Cancer, Volume 129, Issue 16, Page 2440-2440,
Tag: Lung Cancer
Overall lung cancer screening rates low
Cancer, Volume 129, Issue 16, Page 2440-2440,
Promoting lung cancer screening of high‐risk patients by primary care providers
Abstract Background Lung cancer screening (LCS) with low-dose computed tomography (LDCT) of the chest of eligible patients remains low. Accordingly, augmentation of appropriate LCS referrals by primary care providers (PCPs) was sought. Methods The quality improvement (QI) project was performed between April 2021 and June 2022. It incorporated patient education, shared decision-making (SDM) with PCPs,… Continue reading Promoting lung cancer screening of high‐risk patients by primary care providers
Promoting lung cancer screening of high‐risk patients by primary care providers
A large, multisite QI project is warranted to address overcoming potential transportation barriers in high-risk patient populations . Twenty-five percent of veterans failed to report to their scheduled screening, and two declined referrals . Lung-RADS scores 4B/4X were more than double the expected prevalence of lung cancer .
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non–small cell lung cancer
PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard-of-care in patients with stage III or unresectable non–small cell lung cancer (NSCLC) Black patients comprised just 2% of randomized patients in this trial .
Safety and efficacy of durvalumab after concurrent chemoradiation in Black patients with locally advanced non–small cell lung cancer
PACIFIC trial established consolidative durvalumab after concurrent chemoradiation as standard-of-care in patients with stage III or unresectable non–small cell lung cancer (NSCLC) Black patients comprised just 2% of randomized patients in this trial .
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Patients with DM had a significantly shorter median progression-free survival (PFS) and overall survival . The time on pembrolizumab treatment was shorter in diabetic patients, with only 19.6% remaining on treatment at 12 months compared to 31.7% of the nondiabetic patients . More work is needed to verify our findings and explore similar effects in… Continue reading Association between diabetes mellitus and reduced efficacy of pembrolizumab in non–small cell lung cancer
Adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations and cancer risk: A systematic review and meta‐analysis
A systematic review and meta-analysis of studies investigating associations between a score for adherence to the 2018 Cancer Prevention Recommendations and cancer risk was conducted . The summary risk ratio per 1-point increment in adherence score was 0.89 (95% CI) for breast cancer . There were no significant associations with prostate or other cancers .
Adherence to the 2018 World Cancer Research Fund (WCRF)/American Institute for Cancer Research (AICR) Cancer Prevention Recommendations and cancer risk: A systematic review and meta‐analysis
A systematic review and meta-analysis of studies investigating associations between a score for adherence to the 2018 Cancer Prevention Recommendations and cancer risk was conducted . The summary risk ratio per 1-point increment in adherence score was 0.89 (95% CI) for breast cancer . There were no significant associations with prostate or other cancers .